Company news
TScan Therapeutics, Inc. news in 2022
TScan Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 8, 2022
TScan Therapeutics Announces Upcoming Virtual Investor Event
November 6, 2022
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
November 2, 2022
TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
October 4, 2022
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
September 11, 2022
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 9, 2022
TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology
July 10, 2022
TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer
July 6, 2022
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
May 30, 2022
TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting
May 1, 2022
TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance
April 10, 2022
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
March 8, 2022
TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
January 23, 2022
TScan Outlines 2022 Priorities as Programs Enter Clinic
January 9, 2022
Decks in 2022
- Investor Presentation (May 2022)
Investor deck · 39 slides · May 2022